PLRX

PLIANT THERAPEUTICS, INC. PLRX

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Net income

$-22.37M

Quarter to Jun 30

Free cash flow

$-12.80M

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$54.83M total
TANG CAPITAL MANAGEMENT LLC
$7.00M0.0%
ADAR1 Capital Management, LLC
$6.28M+113.1%
VANGUARD CAPITAL MANAGEMENT LLC
$2.78M+4.2%
ACADIAN ASSET MANAGEMENT LLC
$2.75M0.0%
TWO SIGMA INVESTMENTS, LP
$2.58M+0.4%
CITADEL ADVISORS LLC
$2.44M-33.6%
RENAISSANCE TECHNOLOGIES LLC
$2.34M+10.6%
Monaco Asset Management SAM
$2.21M0.0%
Lynx1 Capital Management LP
$2.05MNew
BML Capital Management, LLC
$1.76M0.0%
Prosight Management, LP
$1.56M-17.8%
Peapod Lane Capital LLC
$1.49M+1.6%
Woodline Partners LP
$1.48M-22.2%
BlackRock, Inc.
$1.31M+5.0%
Ikarian Capital, LLC
$1.14MNew
Eversept Partners, LP
$1.02M0.0%
MARSHALL WACE, LLP
$952.0K-16.1%
Redmile Group, LLC
$880.2K0.0%
JPMORGAN CHASE & CO
$783.9K-20.9%
JACOBS LEVY EQUITY MANAGEMENT, INC
$733.2K-10.5%
GEODE CAPITAL MANAGEMENT, LLC
$660.0K+38.7%
UBS Group AG
$651.8K-46.0%
MILLENNIUM MANAGEMENT LLC
$637.8K-52.6%
BRIDGEWAY CAPITAL MANAGEMENT, LLC
$631.1K0.0%
Connor, Clark & Lunn Investment Management Ltd.
$611.1K+3.6%
See all 86 institutional holders →
Reading the latest SEC filing…

Key Metrics

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

ROIC

Q2 2026
EDGAR

Free Cash Flow

Q2 2026
EDGAR

Debt/Equity

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/PLRX

Earnings Per Share

13fpro.ai/company/PLRX

Loading ratio trend…

PLRX key financials by period

Reported revenue, net income and operating margin by fiscal year, from PLIANT THERAPEUTICS, INC.'s annual filings on SEC EDGAR.

PLIANT THERAPEUTICS, INC. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2023$1.6M$-161.3M—
FY 2022$9.7M$-123.3M—
FY 2021$7.6M$-97.3M—
FY 2020$41.8M$-41.5M-99.6%
FY 2019$57.1M$-631.0K-2.2%
Source: PLRX filings on SEC EDGAR →

PLRX insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About PLIANT THERAPEUTICS, INC. (PLRX): stock profile, AI score and financials

PLIANT THERAPEUTICS, INC. (PLRX) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. PLRX is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q2 2026), PLIANT THERAPEUTICS, INC. reports net income of $-22.4M, free cash flow of $-12.8M. Top institutional holders of PLRX by reported 13-F value include TANG CAPITAL MANAGEMENT, ADAR1 Capital Management, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. PLRX trades on the Nasdaq exchange and files with the SEC under CIK 1746473. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PLRX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for PLIANT THERAPEUTICS, INC. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1746473 →